Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
31 hedge funds and large institutions have $52.2M invested in Marinus Pharmaceuticals, Inc in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 13 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
18% less funds holding
Funds holding: 38 → 31 (-7)
32% less capital invested
Capital invested by funds: $76.3M → $52.2M (-$24M)
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.48M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$484K |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$366K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$121K |
| 5 |
Bank of New York Mellon
New York
|
+$87.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.56M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.53M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$1.48M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$280K |
| 5 |
NC
Nexthera Capital
New York
|
-$191K |
MRNS Hedge Fund Activity: Q1 2016 in Review
31 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2016, worth a combined $52.2M — down 32% from $76.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of MRNS and 6 opened new positions — a net loss of 7 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Franklin Resources, adding an estimated $1.48M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.56M sold.
- 31 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2016, down from 38 in Q4 2015.
- Funds reported $52.2M of Marinus Pharmaceuticals, Inc stock for Q1 2016, down 32% quarter-over-quarter.
- 6 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2016 and 13 closed out, a net change of -7 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q1 2016 was Franklin Resources, an estimated $1.48M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2016 was Point72 Asset Management, an estimated $1.56M sold.
Based on aggregated 13F filings for Q1 2016.